Dianthus Therapeutics (NASDAQ:DNTH) Price Target Raised to $67.00 at Robert W. Baird

Dianthus Therapeutics (NASDAQ:DNTH) had its target price hoisted by Robert W. Baird from $50.00 to $67.00 in a report released on Tuesday morning,Benzinga reports. The brokerage currently has an outperform rating on the stock.

Other equities analysts have also recently issued reports about the stock. William Blair assumed coverage on shares of Dianthus Therapeutics in a research report on Wednesday, July 2nd. They set an “outperform” rating on the stock. HC Wainwright reaffirmed a “buy” rating and set a $40.00 price objective on shares of Dianthus Therapeutics in a research note on Monday. Finally, Wedbush lifted their target price on Dianthus Therapeutics from $34.00 to $42.00 and gave the stock an “outperform” rating in a report on Thursday, August 21st. Eight research analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the company has an average rating of “Buy” and an average target price of $60.67.

Dianthus Therapeutics Trading Up 11.9%

Shares of NASDAQ DNTH opened at $35.57 on Tuesday. The firm’s 50-day moving average is $21.89 and its 200-day moving average is $20.20. Dianthus Therapeutics has a 1 year low of $13.36 and a 1 year high of $36.57. The firm has a market capitalization of $1.14 billion, a PE ratio of -10.94 and a beta of 1.46.

Dianthus Therapeutics (NASDAQ:DNTH) last released its earnings results on Thursday, August 7th. The company reported ($0.88) EPS for the quarter, missing analysts’ consensus estimates of ($0.86) by ($0.02). Dianthus Therapeutics had a negative return on equity of 34.72% and a negative net margin of 2,364.56%.The business had revenue of $0.19 million for the quarter, compared to analyst estimates of $0.87 million. As a group, equities research analysts anticipate that Dianthus Therapeutics will post -2.61 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Dianthus Therapeutics

A number of large investors have recently added to or reduced their stakes in the company. Raymond James Financial Inc. bought a new stake in shares of Dianthus Therapeutics in the second quarter worth $27,000. US Bancorp DE lifted its position in Dianthus Therapeutics by 2,013.3% during the 1st quarter. US Bancorp DE now owns 1,585 shares of the company’s stock worth $29,000 after buying an additional 1,510 shares in the last quarter. BNP Paribas Financial Markets acquired a new position in shares of Dianthus Therapeutics during the 4th quarter worth about $59,000. GAMMA Investing LLC grew its holdings in shares of Dianthus Therapeutics by 3,030.6% in the 1st quarter. GAMMA Investing LLC now owns 3,882 shares of the company’s stock valued at $70,000 after acquiring an additional 3,758 shares in the last quarter. Finally, Tower Research Capital LLC TRC increased its position in shares of Dianthus Therapeutics by 330.7% in the second quarter. Tower Research Capital LLC TRC now owns 4,320 shares of the company’s stock valued at $80,000 after acquiring an additional 3,317 shares during the last quarter. Institutional investors own 47.53% of the company’s stock.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.